<DOC>
	<DOCNO>NCT00063154</DOCNO>
	<brief_summary>The purpose study determine study drug pertuzumab effective treat patient advanced lung cancer recur follow prior chemotherapy .</brief_summary>
	<brief_title>Safety Effect Pertuzumab Patients With Advanced Non-Small Cell Lung Cancer , Which Has Progressed After Prior Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<criteria>Signed informed consent Tumor accessible biopsy willingness undergo tumor biopsy Age &gt; = 18 year Recurrent , histologically document NSCLC , i.e. , squamous cell , adeno , large cell anaplastic carcinoma . A cytologic diagnosis acceptable ( i.e . fineneedle aspiration pleural fluid cytology ) . Measurable disease least one lesion accurately measure least one dimension ( bilateral dimension record ) . Each lesion must &gt; = 20 mm measure conventional technique , include palpation , plain Xray , CT , MRI , &gt; = 10 mm measure spiral CT . Progression disease , completion , least one prior chemotherapy regimen , contain either platinum , taxane vinca alkaloid ( e.g . vinorelbine ) . There upper limit number prior chemotherapy regimen subject may receive . Recovery reversible acute effect prior chemotherapy regimen radiotherapy NCICTC Grade &lt; = 1 ( exclude alopecia ) ECOG performance status 0 1 Use effective mean contraception men , woman childbearing potential Absolute neutrophil count &gt; = 1500/mL , platelet count &gt; = 75,000/mL hemoglobin &gt; = 9 g/dL ( hemoglobin may support transfusion erythropoietin approve hematopoietic growth factor ; darbepoetin [ Aranesp ] permit ) Serum bilirubin &lt; = 1.5 x upper limit normal ( ULN ) alkaline phosphatase , AST , ALT &lt; = 2.5 x ULN ( ALT , AST , alkaline phosphatase &lt; = 5 x ULN subject liver metastasis ) Serum creatinine &lt; = 1.5 x ULN Internalized normalize ratio ( INR ) &lt; 1.5 activate partial thromboplastin time ( aPTT ) &lt; 1.5 ULN ( except subject receive warfarin ) Prior treatment HER pathway inhibitor ( e.g. , Herceptin [ Trastuzumab ] , Iressa [ gefitinib ] , Tarceva [ erlotinib hydrochloride ] , C225 , CI1033 , TAK165 Treatment experimental anticancer agent within 4 week prior Day 1 Histologically document bronchioalveolar carcinoma History clinical radiographic evidence central nervous system brain metastasis Ejection fraction , determine ECHO , &lt; 50 % Uncontrolled hypercalcemia ( &gt; 11.5 mg/dL ) Prior exposure &gt; 360 mg/m2 doxorubicin liposomal doxorubicin , &gt; 120 mg/m2 mitoxantrone , &gt; 90 mg/m2 idarubicin Ongoing corticosteroid treatment , except subject stable dos &lt; 20 mg prednisone daily ( equivalent ) , subject take corticosteroid nonmalignant condition History malignancy within 5 year Day 1 except adequately treat carcinoma situ cervix , ductal carcinoma situ breast , basal squamous cell skin cancer History serious systemic disease , uncontrolled hypertension ( diastolic blood pressure &gt; 100 mmHg two consecutive occasion ) , unstable angina , congestive heart failure , myocardial infarction within 6 month prior Day 1 , unstable symptomatic arrhythmia require medication ( subject chronic atrial arrhythmia , i.e. , atrial fibrillation , paroxysmal supraventricular tachycardia , control hypertension eligible ) Ongoing liver disease , include viral hepatitis , current alcohol abuse , cirrhosis Active infection require IV antibiotic Known human immunodeficiency virus infection Pregnancy lactation Major surgery significant traumatic injury within 3 week prior Day 1 , exception tumor biopsy purpose study Inability comply study followup procedure Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render subject high risk treatment complication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Lung cancer</keyword>
</DOC>